The development of drug resistance by tumor cells is a major obstacle to the cure of human malignancy. Cyclosporin A (CsA) completely reverses primary resistance to vincristine and cross resistance to daunorubicin in a pleiotropic drug-resistant subline of human T cell acute lymphatic leukemia. This subline is over 50-fold resistant to vincristine and fivefold resistant to daunorubicin. CsA has little effect on vincristine or daunorubicin activity in drug-sensitive parental leukemia and corrects daunorubicin resistance without altering cellular daunorubicin accumulation.
Introduction
There has been recent interest in the ability of calcium channel blocking agents and calmodulin inhibitors to enhance the responses of drug-resistant tumor cells to vinca alkaloids and to anthracycline antibiotics (1) (2) (3) . The mechanism of this effect relates in part to the ability ofthese agents to inhibit the enhanced active efflux of vinca alkaloids and anthracycline antibiotics by resistant cells, resulting in increased cellular drug retention (1, 4) . Since the acquisition of equimolar concentrations of anthracyclines by anthracycline-resistant compared with anthracycline-sensitive tumor cells fails to restore equivalent cytotoxic drug effect to these cells, the mechanism by which calcium channel blocking agents and calmodulin inhibitors restore drug sensitivity must extend beyond drug retention (5, 6) . We now report that cyclosporin A (CsA)' reverses vincristine (VCR) resistance in VCR-resistant human T cell acute lymphatic leukemia (ALL) and corrects the daunorubicin cross resistance of this leukemia subline. CsA has little effect on VCR or daunorubicin activity in drug-sensitive parental ALL, nor does it alter uptake or efflux of daunorubicin by daunorubicin-resistant ALL cells.
1. Abbreviations used in this paper: ALL, acute lymphatic leukemia; CsA, cyclosporin A; ED50, 50% effective dose; L0, drug-sensitive tumor line; L100, VCR-resistant subline; VCR, vincristine.
A VCR-resistant subline ofGM3639 cells (Human Genetic Mutant Cell Repository, Camden, NJ) was developed by continuous in vitro exposure of GM3639 ([) cells, initially to sublethal and then to progressively increased concentrations of vincristine as previously described (7) . The drug-resistant subline (1,o) , grown continuously in 100 nM VCR, shows primary resistance to vincristine and cross resistance to daunorubicin and to VP-16 (7) . VCR sensitivity of L0 and L100 cells is measured in a cytotoxicity assay, in which cell viability in increasing concentrations of VCR is compared with cell viability in the absence of VCR (7). Daunorubicin sensitivity of L4 and L1_o cells is measured by the ability of daunorubicin to inhibit thymidine incorporation into DNA in these cell lines as previously described; this method correlates well with responses of daunorubicin-sensitive and daunorubicin-resistant Ehrlich ascites carcinoma in vivo (2) . Uptake and efflux of [3H]daunorubicin by these leukemic cell lines is measured by previously described methods (8) . CsA was kindly provided in powder form by Dr. David Winter, Sandoz, Inc., East Hanover, NJ. [3Hldaunorubicin uptake by drug-sensitive vs. drug-resistant cells. The current series of experiments shows no effect of CsA on daunorubicin efflux from L10o cells. Fig. 3 (2) . The daunorubicin-resistant Ehrlich ascites carcinoma subline is similar to the L100 subline since it also shows only slightly impaired uptake of daunorubicin compared with daunorubicin-sensitive parental tumor (8) . Our current experiments also show that CsA fails to effect daunorubicin uptake or efflux by L0oo cells, indi- cating that the restoration of daunorubicin responsiveness by CsA must depend on mechanisms independent of modified daunorubicin transport.
Results
The CsA-restorative mechanism is unclear but may relate to calmodulin inhibition. It has recently been reported that human ALL cells have a 10-fold greater concentration of calmodulin than normal peripheral blood lymphocytes and that CsA is a potent inhibitor of T lymphocyte calmodulin (9, 10).
., . Ci/mmol, final concentration 5 ,ug/ml daunorubicin and 5 MCi/ml).
Immediately and at designated time points, triplicate aliquots of 200 ,ul (at 37°C) were placed in microtiter plate wells and harvested onto glass fiber filters using a titertek multiple sample harvester. The filters were dried and counted in a PPO/POPOP/toluene liquid scintillation system. Efflux at 37°C was measured after 30 min of drug uptake. Aliquots were removed from the uptake suspension, centrifuged, washed, and resuspended in same volume of RPMI 1640. Triplicate 200-Ml samples were taken immediately and at indicated time points and processed as above.
antibiotics in pleiotropic drug-resistant cells (5, 6) . It has therefore been suggested that these agents, and it now appears that CsA, may promote favorable chemotherapeutic drug interactions at the membrane level or enhance intracellular drug binding (5, 12) .
The clinical use ofcalcium channel blocking agents has been limited by high concentration requirements (14) . However, since large doses of CsA have been administered to man with reasonable safety, and concentrations approaching those that are required for restoration of VCR and daunorubicin responses in ALL in vitro are achievable in vivo, CsA may prove to be a useful agent in the treatment of vinca alkaloid and anthracycline antibiotic-resistant neoplasia (15) (16) (17) .
